Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EACH: Avelumab and Cetuximab in Recurrent/Metastatic Head and Neck Squamous Cell Cancer
NCT03494322Phase 2Completed
- Sponsor
- University College London
- Start
- Jul 2018
- Primary completion
- Sep 2021
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of avelumab and KL-140 in head and neck squamous cell carcinoma (HNSCC) (2 arms), sponsored by University College London. Primary endpoints: Occurrence of dose limiting toxicity at 6 weeks and Disease control rate at 24 weeks. Started Jul 2018; status: completed.
02
Drugs
avelumabKL-140
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT03494322.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03494322.